Announcement PDF 17 September 2025 BPH GLOBAL LTD ACN 009 104 330 Company Announcements Platform Australian Securities Exchange BPH Global has successfully raised capital to accelerate growth in its seaweed operations Highlights • The Company receives commitments from investors of $1,100,000 for a private placement • $700,000 allocated to purchase of seaweed and to support operations in Indonesia • $200,000 allocated to R&D projects • R&D initiatives focused on developing high-margin products The Board of BPH Global Ltd (ASX: BP8) (Company) is pleased to announce that it has secured firm commitments from institutional, professional and sophisticated investors to raise up to $1,100,000 (before expenses), through the issue of 550,000,000 fully paid ordinary shares (Placement Shares) at an issue price of $0.002 per Share (Placement). The Placement offer comprised a placement of up to 550,000,000 Placement Shares in BP8 at A$0.002 per Placement Share to raise up to $1,100,000 in two tranches with one (1) free attaching option for each two (2) Placement Shares allotted. The exercise price of the options will be A$0.004 and expire 2 years from their issue date (Free Attaching Options). Managing Director Matthew Leonard commented: “We are pleased with the strong demand for this placement, which strengthens our balance sheet and ensures we are well positioned to drive growth across our Indonesian seaweed operations and the R&D-based product pipeline”. Issue of securities The Company will issue the Placement Shares to participants in the Placement in two (2) tranches: • Tranche 1 comprises 250,000,000 Placement Shares in the Company to be issued as follows: o 146,000,000 Placement Shares pursuant to the Company's share issuing capacity under ASX Listing Rule 7.1; and o 104,000,000 Placement Shares pursuant to the Company's share issuing capacity under ASX Listing Rule 7.1A. • Tranche 2 comprises up to 300,000,000 Placement Shares and will be issued post the Company’s annual general meeting to be held this November (2025 AGM), subject to shareholders approving the issue of those Placement Shares at that meeting. Tranche 2 includes an application for 25,000,000 Placement Shares to raise $50,000 from entities associated with Company Director, Francesco Cannavo, which will be issued subject to approval for the purposes of ASX Listing Rule 10.11. Pending BP8 shareholder approval at the 2025 AGM, the Free Attaching Options will be issued for each two (2) Placement Shares allotted. Use of funds The Company intends to use the funds raised from the Placement as set out in the table below: Funds Raised Proposed Use (A$1,100,000) Funding of seaweed Indonesia-based seaweed operations $700,000.00 R&D projects $200,000.00 Working capital $140,000.00 Costs of Offer $60,000 Total A$1,100,000 Indonesia-based seaweed operations • Seaweed Business: Why Indonesia – The strategic rationale: Indonesia continues to present as a strong growth opportunity for BP8’s seaweed operations due to: o Market Leadership: Indonesia is the largest global producer of seaweed (60% of global supply). o Cost & Logistics Efficiency: Indonesia provides many operational advantages including competitive production costs, the availability of Government incentives, and proximity to key Asian-based export markets. o Sustainability & ESG Compliance: The ESG benefits of seaweed farming which underpin BP8’s seaweed business provides the BP8 Group with the means to comply with its ESG compliance obligations and aligns with the Indonesian Government’s policies on sustainable aquaculture. • Seaweed Business: Key assets and operations include: o Warehouse Lease in Makassar: BP8 Indonesia has secured a lease on a 550m² warehouse in Makassar, South Sulawesi—a key seaweed processing hub. The facility has a storage capacity of up to 1,000 MT of raw seaweed per month and is currently undergoing Good Manufacturing Practice (GMP) and Hazard Analysis and Critical Control Point (HACCP) certification. It will feature § A fully equipped Quality Control (QC) laboratory; § A hydraulic press for packaging and loading dried seaweed; and § Dedicated administration, QC, and management teams. § Completion of the commissioning of this facility will further enhance BP8 Indonesia’s existing seaweed processing and supply operations. o Ulva and Caulerpa Cultivation Pilot: BP8 Indonesia has also leased and begun operating onshore seaweed cultivation tanks in Takalar Regency, South Sulawesi, focusing on Ulva (sea lettuce) and Caulerpa (sea grapes). This pilot project—supported by the United Nations Industrial Development Organization (UNIDO)—aims to scale the use of closed-system raceway pools for Ulvacultivation, with applications in the food and cosmetics industries. The current production capacity is 1 MT per month, with plans underway for future expansion. o Farmer and Cooperative Engagement: Ongoing collaboration with local farmers and cooperatives across the Indonesian archipelago ensures BP8 Indonesia will maintain a consistent, year-round seaweed supply for domestic and regional markets. o Offtake Partnerships: BP8 Indonesia is actively sourcing offtake partners in addition to its existing customer base, particularly carrageenan and seaweed-based product o manufacturers in China and Indonesia. Discussions are underway to negotiate additional long-term offtake agreements to support commercial scale-up. Supply Chain & Market Expansion: In addition to its work with local farmers, BP8 Indonesia is actively collaborating with cooperatives across the Indonesian archipelago to ensure a consistent year-round seaweed supply. Research and Development Projects • Seaweed-based Rare Earth Elements (REEs), Precious and Critical Minerals : The Company‘s wholly owned, Singapore-based subsidiary Stemcell United Pte Ltd (BP8 Singapore) has entered into a Master Services Agreement with Singapore-based company Marchwood Laboratory Services Pte Ltd (MLS) for sea plant and seaweed tissue metal content measurement in three categories: o Rare earth elements (REEs), including Lanthanum (La), Terbium (Tb), Yttrium (Y) and Neodymium (Nd); o Precious minerals; and o Critical minerals. BP8 will partner with MLS, a Singapore-based professional laboratory accredited by SACSINGLAS under ISO 17025. Equipped with state-of-the-art ICP-MS (Inductively coupled plasma mass spectrometry) technology and operating under USEPA standards, MLS will enable precise measurement of elemental concentrations in seaweed. This work represents an upgrade from previous collaborations with Temasek Polytechnic (Singapore), strengthening BPH Global’s technical platform in the rapidly emerging intersection of blue economy solutions and advanced materials recovery. • Green Seaweed Kefir Beverages: Following the successful completion of the Singapore Polytechnic R&D program, the Company will progress the probiotic and postbiotic beverage concepts toward potential market entry. Key steps include: o Independent Review Completed: R&D confirmation that the formulations deliver the intended functional health benefits and that the R&D outcomes are robust. o Safety & Shelf-Life Testing: Undertake extended microbiological, shelf stability, and packaging compatibility studies to ensure both formulations meet safety and quality standards for their intended shelf lives (three (3) days and 12 months respectively). o Consumer Acceptability Trials: Ongoing taste panels and sensory evaluations will continue, although initial feedback indicates the beverages already satisfy taste and flavour standards. o Regulatory & Labelling Compliance: Assess the products against food safety regulations in target markets and ensure health claims are substantiated and compliant. o Pilot Manufacturing & Scalability: Transition from laboratory-scale production to pilotscale trials to confirm batch consistency, optimise processing parameters, and evaluate cost-effectiveness of large-scale manufacturing. o Commercial Partnerships: Identify and secure distribution and manufacturing partners, including opportunities to license production rights to qualified third parties. o Market Positioning & Appeal: Develop branding, pricing, and go-to-market strategies aligned with consumer demand for sustainable, plant-based functional health products. • Bioremediation: The Company has developed seaweed-based solutions which offer a sustainable, scalable approach to rehabilitating coastal and waterway ecosystems, aligning with the Company’s environmental mission and commitment to improved health outcomes - not only for directly affected communities, but also more broadly through the recovery of strategic minerals for use in traditional medicine and pharmaceutical applications. The Company aims to partner with industries that discharge pollutants into coastal areas and waterways, focusing on delivering effective, nature-based bioremediation solutions. By identifying and cultivating seaweed species or coastal plants best suited to specific polluted environments—particularly those that thrive in affected waters and act as hyperaccumulators of pollutants and valuable minerals—the Company seeks to provide sustainable environmental restoration services. This approach not only supports ecosystem rehabilitation but also creates potential value from the harvested biomass through the recovery of strategic minerals for applications in traditional medicine and pharmaceuticals. As part of its strategic focus, the Company is targeting bioremediation opportunities within the mining sector—specifically the nickel and coal industries—where the environmental impact of operations presents a pressing need for remediation solutions. In support of this strategy, the Company has undertaken preliminary due diligence on selected nickel and coal operations in Indonesia, including a recent site visit to a nickel mine and refinery. Joint Lead Managers The Company appointed Sanlam Private Wealth Pty Ltd ABN 18 136 960 775, AFSL No 337927 (“Sanlam”) & Novus Capital ABN 32 006 711 995, AFSL No 238168 (“Novus”) as joint lead managers for the Placement. Sanlam and Novus will be paid in aggregate a 6% capital raising success fee plus GST on the gross Placement funds raised. Sanlam (and/or its nominee) will also be paid a cash fee of $8,000 (exclusive of GST) and be issued with 5,000,000 BP8 shares subject to shareholder approval at the 2025 AGM as consideration for the provision its broker services to the Company. Novus (and/or its nominee) will also be issued with 5,000,000 BP8 shares as consideration for the provision its broker services to the Company, subject to shareholder approval at the 2025 AGM. - END Authorised for release by: The Board of BPH Global Ltd For further information, please visit our website at www.bp8global.com or contact the Company Secretary on 03 9088 2049.